Valuation: Celgene

Market Cap 77.04B 68.83B 64.22B 58.33B 110B 7,452B 111B 772B 301B 3,790B 289B 283B 12,184B P/E 2017
28.7x
P/E 2018 11.6x
Enterprise Value 91.26B 81.54B 76.07B 69.1B 130B 8,828B 131B 914B 357B 4,490B 343B 335B 14,433B EV / Sales 2017
6.61x
EV / Sales 2018 3.86x
Free-Float
-
Yield 2017 *
-
Yield 2018 -
15/06/23 Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation CI
08/09/21 Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation CI
22/06/21 Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity CI
23/02/21 Celgene Corporation Issues Notice of Redemption of Notes CI
04/02/21 Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion CI
05/01/21 Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors CI
23/12/20 Amgen : Signs Licensing Agreement With Medicines Development for Global Health MT
05/11/20 Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook MT
23/09/20 Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors CI
22/09/20 Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors CI
26/03/20 Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene CI
11/03/20 Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors CI
05/03/20 Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis CI

Financials

2017 2018
Net sales 13B 11.62B 10.84B 9.85B 18.54B 1,258B 18.68B 130B 50.89B 640B 48.82B 47.76B 2,056B 15.28B 13.65B 12.74B 11.57B 21.79B 1,478B 21.95B 153B 59.8B 752B 57.37B 56.13B 2,417B
Net income 2.94B 2.63B 2.45B 2.23B 4.19B 284B 4.22B 29.45B 11.51B 145B 11.04B 10.8B 465B 4.05B 3.62B 3.37B 3.06B 5.77B 391B 5.81B 40.53B 15.83B 199B 15.19B 14.86B 640B
Net Debt 3.79B 3.39B 3.16B 2.87B 5.41B 367B 5.45B 38B 14.84B 187B 14.24B 13.93B 600B 14.22B 12.71B 11.85B 10.77B 20.28B 1,376B 20.43B 142B 55.66B 700B 53.39B 52.23B 2,249B
Logo Celgene
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. CELG Stock